The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity

BACKGROUND: HER2-positive breast cancers exhibit high rates of innate and acquired resistance to trastuzumab (TZ), a HER2-directed antibody used as a first line treatment for this disease. TZ resistance may in part be mediated by frequent co-expression of EGFR and by sustained activation of the mamm...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Dragowska, Wieslawa H, Weppler, Sherry A, Qadir, Mohammed A, Wong, Ling Yan, Franssen, Yannick, Baker, Jennifer HE, Kapanen, Anita I, Kierkels, Guido JJ, Masin, Dana, Minchinton, Andrew I, Gelmon, Karen A, Bally, Marcel B
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2011
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3207940/
https://ncbi.nlm.nih.gov/pubmed/21961653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-11-420
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge